Forte Biosciences shares surge 14.81% intraday after Guggenheim analyst initiates coverage with a buy rating and $75 price target.

Forte Biosciences, Inc. surged 14.81% intraday, following Guggenheim analyst coverage with a buy rating and $75 price target, citing the potential of CD122 blockade therapy in severe autoimmune diseases. The company also released its Q2 2025 financial report, showing a net loss of $11.25 million and a loss per share of $0.96.